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Abstract
Introduction: Core disease activity indicators of rheumatoid arthritis (RA) have been found to be limited in predicting
joint destruction progression. Matrix metalloproteinase (MMP) 3 plays an essential role in joint destruction and was
found elevated in some remission patients. We aimed to monitor dynamic core disease activity indicators and serum
MMP-3 for one year and evaluate their value for predicting radiographic progression.
Methods: Patients with active RA (Simplified disease activity index > 3.3) were treated according to the treat-to-target
strategy. Serum MMP-3 was detected by enzyme-linked immunosorbent assay and clinical data were collected
simultaneously at 0, 1st, 3rd, 6th and 12th month. X-ray assessment of hand/wrist was repeated at baseline and the 12th
month and a change of total Sharp score > 0.5 units was defined as radiographic progression.
Results: Fifty-six patients completed one year follow-up and 29 % showed radiographic progression. Although not
significantly different at baseline, serum MMP-3 and all core disease activity indicators, except for erythrocyte
sedimentation rate, at the 12th month were significantly higher in the progressive group than in the non-progressive
group. Among sixteen progressive patients, 69 % achieved the therapeutic target and 56 % had continuous elevated
serum MMP-3, 38 % had continuous elevated serum MMP-3 and normal C-reactive protein (CRP) at the 6th month.
Log-rank tests and repeated measures analysis revealed a significant difference in dynamic serum MMP-3 between
progressive and non-progressive patients. Receiver operating characteristic curve and univariate logistic regression
analysis showed that elevated serum MMP-3 at 0, 1st, 3rd and 6th months, compared with CRP at the 1st month,
were significant predictors for one-year radiographic progression (MMP-3 odds ratio (OR):10.500 ~ 27.000, all P < 0.05;
CRP: OR = 7.400, P = 0.011).
Conclusions: Our data showed that continuously elevated serum MMP-3 for 3 ~ 6 months predicted one-year
radiographic progression which implied that monitoring of dynamic serum MMP-3 combined with core disease
activity indicators may be more helpful for predicting radiographic progression and treatment decision in RA.
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Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune
disease characterized by chronic synovitis and joint
destruction which eventually lead to disability. It is a
heterogeneous disease with a wide range of clinical
manifestations from mild joint swelling with slowly pro-
gressive to severe polyarthritis with rapidly progressive de-
struction of cartilage and bone [1]. According to the
current recommendations, RA treatment decision-making
is mainly based on disease activity, and adjustment of ther-
apy adheres to the treat-to-target (T2T) strategy which tar-
get is remission or low disease activity (LDA) [2]. However,
a limitation of this strategy has been found in the preven-
tion of structure destruction [3]. Radiographic progression
has been reported in some remission RA patients, which
implies the limitation of core disease activity indicators in
predicting radiographic progression [4]. Considering the
common disease activity indicators are unspecific for arth-
ritis, novel biomarkers, such as inflammatory cytokines,
destructive enzymes, breakdown products from collage-
nous and non-collagenous components of cartilage, and
novel multi-biomarkers score containing several bio-
markers, have been rapidly developed for predicting struc-
tural destruction progression in RA [5, 6].
Matrix metalloproteinase (MMP) 3 is a proteinase se-
creted by synovial fibroblasts and chondrocytes in joints.
Active MMP-3 can accelerate joint destruction in RA by
degrading aggrecan core protein, cartilage link protein, fi-
bronectin, and collagen types IV, VII, IX and XI [7]. Serum
MMP-3 had been well studied as an indicator of disease
activity in RA. Our previous studies showed that serum
MMP-3 level in RA was increased and positively correlated
with disease activity, histological synovitis and synovial
MMP-3 expression. However, some patients with remis-
sion or LDA also showed elevated serum MMP-3 and
the outcome of these patients has been rarely reported
[8, 9]. Considering the relationship between serum
MMP-3 and joint destruction, we hypothesized that
continuously elevated serum MMP-3 might be a pre-
dictor of radiographic progression. Here, we performed
a prospective cohort study to monitor dynamic core
disease indicators and serum MMP-3 for one year, and




Patients with RA who fulfilled the 1987 revised criteria of
the American College of Rheumatology (ACR) [10] or
2010 ACR/EULAR classification criteria for RA [11] were
recruited from the Department of Rheumatology of Sun
Yat-sen Memorial Hospital, Guangzhou, People’s Republic
of China. Inclusion criteria also included: patients with ac-
tive disease activity, defined as simplified disease activity
index (SDAI) > 3.3 [12] and poor prognosis of one or
more of the following features: functional limitation
(Health Assessment Questionnaire score ≥ 1 [13]),
positive rheumatoid factor (RF) or anti-cyclic citrulli-
nated peptide antibody (anti-CCP), extraarticular dis-
ease (e.g., presence of rheumatoid nodules, secondary
Sjogren’s syndrome, RA vasculitis, Felty’s syndrome,
and RA lung disease) and bony erosions by radiography
[14]. Exclusion criteria included: relevant concurrent
liver disease (aspartate aminotransferase > 100 IU/L or
alkalinephosphatase > 100 IU/L), renal disease (serum cre-
atinine > 1.5 mg/dl), hematological disease (total white
blood cell count < 4 × 109/L, platelet count < 100 × 109/L),
or severe respiratory disease, malignancy, pregnancy or
plans to become pregnant, and psychological problems
that would make adherence to the study protocol impos-
sible. This study was conducted in compliance with the
Helsinki Declaration. The Medical Ethics Committee of
Sun Yat-sen Memorial Hospital approved the protocol. All
patients agreed to participate in this study and gave writ-
ten informed consent.
Treatment
All patients were treated according to the 2008 ACR rec-
ommendations for the management of RA [14]. Therapy
was decided according to the disease duration, disease ac-
tivity, presence of poor prognosis features and patients’
willingness. Disease duration was divided into three cat-
egories: < 6 months (short), 6–24 months (intermediate),
and > 24 months (long) [14]. Disease activity defined by
SDAI was divided into four categories: > 26.0 [high disease
activity (HDA)], > 11.0 and ≤ 26.0 [moderate disease
activity (MDA)], > 3.3 and ≤ 11.0 [low disease activity
(LDA)], and ≤ 3.3 (remission) [12]. Adjustment of therapy
was based on the T2T strategy adherence to the disease
activity measured by SDAI. The therapeutic target was
defined as remission (primary target) or LDA (alternative
target) measured by SDAI and patients were divided into
a T2T-achieving group (defined as SDAI remission + LDA
at the 12th month) and a T2T-non-achieving group
(MDA+HDA at the 12th month).
Clinical assessments
All patients were followed up at regular intervals in-
cluding the same predefined assessment points (0, 1st,
3rd, 6th, and 12th month) and the following indicators
were assessed: 28-joint tender and swollen joint count
(28TJC and 28SJC, both 0–28), Patient global assess-
ment of disease activity (PtGA, 0–10 cm, 10 = worst
status), Provider global assessment of disease activity
(PrGA, 0–10 cm, 10 = worst status), Pain visual analogue
scale (Pain VAS, 0–10 cm, 10 =most pain), Chinese lan-
guage version of the Stanford health assessment question-
naire (HAQ, 0–3, 3 =most functional disability) [15],
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erythrocyte sedimentation rate [(ESR) mm/h, normal range:
0–20 mm/h (female), 0–15 mm/h (male)], C-reactive pro-
tein [(CRP), mg/dl, normal range: 0–0.5 mg/dl], RF (mg/L,
determined by nephelometry, Siemens Healthcare Diagnos-
tics, Munich, Germany, normal range: 0–20 mg/L), and
anti-CCP [U/ml, measured by enzyme-linked immuno-
sorbent assay (ELISA), Aesku Diagnostics, Wendelsheim,
Germany, normal range: 0–18 U/ml]. Disease activity was
assessed with SDAI, clinical disease activity index (CDAI)
and disease activity score in 28 joints (DAS28) with four
variables including CRP [DAS28 (4)-CRP].
Radiographic assessments
Conventional radiographs of bilateral hands and wrists
(anteroposterior view) were performed at baseline and the
12th month visit. All radiographs were scored according to
the Sharp/van der Heijde score of hands by two experi-
enced observers (MJD from rheumatology and ZX from
radiology), who were not aware of the patients’ clinical find-
ings [16]. Sixteen areas for erosion and fifteen for joint
space narrowing of hands were assessed in each hand/wrist.
The maximum score per single joint for erosions is 5, and
for joint space narrowing is 4, with the sum of the erosion
(0 ~ 160) and joint space narrowing (0 ~ 120) subscores
constituting the total Sharp score of hands (0 ~ 280). Reli-
ability and agreement were assessed using an intra-class
correlation coefficient (ICC): the mean ICC for inter-
observer agreement was 0.997. Radiographic progression
was defined as a change of total Sharp score more than 0.5
units [17], and rapid radiographic progression (RRP) was
defined as a change of total Sharp score more than 5 units
from baseline to one year [18].
Sandwich enzyme-linked immunosorbent assay for
determination of serum MMP-3
Serum samples were collected from all the RA patients
after overnight fasting and stored at −80 °C until ana-
lysis. Serum levels of soluble MMP-3 were measured with
a human MMP-3 detection kit (AESKU Diagnostics,
Wendelsheim, Germany) according to the manufacturer’s
instructions. This kit detects total MMP-3 (pro- and active
MMP-3) in human serum. Measurements were done in
duplicate. Serum samples were placed in designated
microwells. In addition, calibrators, negative and posi-
tive controls were added to the designated microwells
to construct a standard curve. The plates were then in-
cubated for 30 min at 26 °C and washed with wash buf-
fer three times. Then 100 μl TMB substrate was added
to each well and incubated for 30 min at 26 °C, pro-
tected from intense light. Then 100 μl of stop solution
was added to each well, using the same order as for the
substrate, and incubated for a minimum of 5 min. The
absorbance of each well was read at 450 nm (optionally
450/620 nm) within 30 min. The normal ranges of serum
MMP-3 concentrations were 18 ng/ml - 60 ng/ml (female)
or 24 ng/ml – 120 ng/ml (male). The assays were
performed blindly, without knowledge of the patient’s
clinical data.
Statistical analysis
Statistical analyses were performed with SPSS for Windows
13.0 statistical software (SPSS Inc., Chicago, IL, USA). Data
are presented as frequencies and percentages for categor-
ical variables and median and interquartile range (IQR)
for continuous variables. The Mann–Whitney or Kruskal-
Wallis rank-sum test was used to compare the differences
of continuous variables between two or three groups. The
Wilcoxon matched-pairs signed ranks sum test was
used to compare the differences of continuous variables
between indicators at baseline and each time point. The
Chi-square test or Fisher exact test was used for cat-
egorical variables in different groups. Univariate and
multivariate logistic regression analyses were used to
identify predictors of radiological progression and con-
trol confounding factors. Variables were included in the
model if P < 0.05 or removed if P > 0.10 according to the
forward selection technique. The one-way analysis of
variance (ANOVA) for repeated measures analysis with
Bonferroni correction for multiple comparisons tests
was used to compare the difference of dynamic disease
activity indicators between two groups. Survival curves
were used to show the ratio of patients with abnormal
disease activity indicators during the therapies. Log-
rank tests were used to compare survival curves of
disease activity indicators between two groups. The abil-
ities of disease activity indicators to predict one-year
radiographic progression were evaluated by positive and
negative predictive values (PPV and NPV, respectively).
The predictive accuracy was assessed by receiver operat-
ing characteristic (ROC) curve analysis with area under
the curve (AUC) and the cutoff point was determined
by the Youden index. All significance tests were two-
tailed and were conducted at the 5 % significance level.
Results
Demographic characteristics of RA patients at baseline
Sixty active RA patients who fulfilled the inclusion cri-
teria were recruited from December 2010 to December
2013. Three patients were lost at the third month visit
for migrating to other provinces and one patient was
diagnosed with lung cancer four months after entry and
excluded. Finally, fifty-six patients completed the study
and were included for statistical analysis. Baseline demo-
graphic and clinical features of 56 patients with RA are
shown in Table 1. The median of disease duration was
24 months ranging from 12 to 55 months. There were
84 % of patients who were RF positive and 82 % of pa-
tients who were anti-CCP positive. There were 46 % of
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Table 1 Baseline demographic and clinical features of RA patients
Characteristics All patients (n = 56) Non-progressive group (n = 40) Progressive group (n = 16) P*
Demographic
Age, yrs, median (IQR) 48 (37 ~ 57) 48 (37 ~ 58) 51 (38 ~ 56) 0.863
Female, n (%) 43 (77) 33 (83) 10 (63) 0.211
Disease duration, mo, median (IQR) 24 (12 ~ 55) 17 (12 ~ 36) 24 (13 ~ 117) 0.154
Short duration, n (%) 5 (9) 3 (1) 2 (13) 0.941
Intermediate duration, n (%) 32 (57) 25 (63) 7 (44) 0.200
Long duration, n (%) 19 (34) 12 (30) 7 (44) 0.326
Core disease activity indicators
ESR (mm/h), median (IQR) 56 (37 ~ 72) 56 (39 ~ 72) 57 (36 ~ 81) 0.856
CRP (mg/dl), median (IQR) 1.4 (0.7 ~ 3.3) 1.3 (0.6 ~ 3.0) 1.7 (0.9 ~ 5.5) 0.214
RF (mg/ml), median (IQR) 206 (61 ~ 475) 211 (42 ~ 465) 178 (69 ~ 510) 0.885
Anti-CCP (U/ml), median (IQR) 132 (32 ~ 300) 78 (26 ~ 300) 178 (53 ~ 425) 0.178
SDAI, median (IQR) 27.7 (16.0 ~ 39.5) 29.3 (14.2 ~ 42.6) 22.1 (16.3 ~ 36.1) 0.479
CDAI, median (IQR) 25.0 (14.3 ~ 36.8) 27.0 (13.0 ~ 39.0) 19.0 (15.3 ~ 32.8) 0.345
DAS28, median (IQR) 5.1 (3.8 ~ 5.9) 5.1 (3.9 ~ 6.1) 4.6 (3.9 ~ 5.7) 0.514
Poor prognosis features
Function limitation, n (%) 30 (54) 20 (50) 10 (63) 0.397
RF positive, n (%) 47 (84) 32 (80) 15 (94) 0.388
Anti-CCP positive, n (%) 46 (82) 31 (78) 15 (94) 0.295
Extraarticular disease, n (%) 1 (2)a 0 1 (2) NA
Bony erosions, n (%) 52 (93) 36 (90) 16 (100) 0.460
Total Sharp score, median (IQR) 11 (3 ~ 25) 8 (3 ~ 16) 22 (13 ~ 43) 0.003
Joint narrow score, median (IQR) 6 (1 ~ 13) 3 (1 ~ 8) 11 (6 ~ 25) 0.014
Erosion score, median (IQR) 5 (2 ~ 13) 4 (1 ~ 7) 13 (8 ~ 20) 0.001
Serum MMP-3 (ng/ml), median (IQR) 175 (57 ~ 365) 123 (45 ~ 276) 316 (195 ~ 563) 0.010
Hepatitis B virus infection, n (%) 5 (9) 2 (5) 3 (19) 0.135
Previous medications
DMARDs and corticosteroids naïve, n (%) 26 (46) 21 (53) 5 (31) 0.253
Corticosteroids, n (%) 17 (30) 11 (28) 6 (38) NA
Irregular, n (%) 9 (16) 5 (13) 4 (25) NA
Prednisolone 10 mg/d, n (%) 4 (7) 4 (10) 0 (0) NA
Prednisolone 5 mg/d, n (%) 4 (7) 2 (5) 2 (13) NA
Methotrexate, n (%) 21 (38) 12 (30) 9 (56) NA
Leflunomide, n (%) 10 (18) 7 (18) 3 (19) NA
Sulfasalazine, n (%) 3 (5) 2 (5) 1 (6) NA
Hydroxychloroquine, n (%) 7 (13) 3 (8) 4 (25) NA
Cyclosporin A, n (%) 2 (4) 2 (5) 0 NA
Infliximab, n (%) 2 (4) 0 2 (12) NA
YSP, n (%) 2 (4) 2 (5) 0 NA
*Compared between non-progressive group and progressive group by Mann–Whitney rank-sum test
RA rheumatoid arthritis, CRP C-reactive protein, ESR erythrocyte sedimentation rate, MMP-3 matrix metalloproteinase-3, RF rheumatoid factor, anti-CCP anti-cyclic
citrullinated peptide antibody, DAS28 Disease Activity Score 28-joint assessment, SDAI simplified disease activity index, CDAI clinical disease activity index,
YSP recombinant human tumor necrosis factor-α receptorII:IgG Fc fusion protein (Yi SaiPu), IQR interquartile range, NA not applicable
aRA vasculitis
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patients without previous corticosteroid or disease-
modifying antirheumatic drugs (DMARDS) therapy and
93 % of patients with bony erosions at baseline. There
was no significant difference in the initial level of serum
MMP-3 among patients with short, intermediate or long
disease duration [247 (50 ~ 352) ng/ml vs 159 (63 ~ 291)
ng/ml vs 279 (41 ~ 440) ng/ml, P = 0.875]. There was also
no significant difference in the percentage of patients with
elevated serum MMP-3 among short, intermediate or long
disease duration groups (60 % vs 78 % vs 68 %, P = 0.593).
There was no significant difference in the initial level of
serum MMP-3 among patients with or without structural
damage already present at baseline [137 (44 ~ 247) ng/ml
vs 175 (63 ~ 380) ng/ml, P = 0.426].
Clinical response and radiographic outcome
All RA patients had poor prognostic features. Thirty
one (55 %) patients were treated with a combination of
conventional synthetic DMARDs (csDMARDs) includ-
ing methotrexate (MTX), leflunomide, hydroxychloro-
quine, sulfasalazine or cyclosporine A. Twenty five (45 %)
patients were treated with a combination of csDMARD
(mostly MTX) and biological DMARD [recombinant
human tumor necrosis factor-α receptor-II (Yi Sai Pu,
biosimilar) or infliximab]. Individualized adjustment of
therapy was based on the T2T strategy and patient’s
willingness. There were 91 % of patients treated with a
combination of csDMARD while 9 % of patients were
treated with a combination of csDMARD and TNF-α
inhibitor at the 12th month. There were 7 %, 18 %, 39 %,
and 34 % of patients who achieved SDAI remission, and
34 %, 41 %, 36 %, and 38 % of patients who achieved SDAI
LDA at the 1st, 3rd, 6th, and 12th month, respectively
(Table 2). At the 12th month, 16 (29 %) patients showed
radiographic progression and five (9 %) patients had
RRP. All patients were then divided into a progressive
group (n = 16) and a non-progressive group (n = 40).
Dynamic change of disease activity indicators and serum
MMP-3
The results of dynamic disease activity indicators and
serum MMP-3 during one year follow-up are shown in
Table 2 and Fig. 1. Although there was no significant dif-
ference at baseline, all core disease activity indicators ex-
cept for ESR at the 12th month were significantly higher
in the progressive group than in the non-progressive
group (all P < 0.05). Among sixteen patients with radio-
graphic progression, eleven (69 %) of them had achieved
the therapeutic target at the 6th month and nine (56 %)
patients had continuously elevated serum MMP-3, six
(38 %) patients had continuously elevated serum MMP-3
and normal CRP at the 6th month. There were 82 % of
the RA patients with elevated CRP and 73 % with elevated
serum MMP-3 at baseline and CRP decreased more
quickly than serum MMP-3 after treatment. There were
54 %, 59 %, 77 %, and 70 % of RA patients with normal
CRP at the 1st, 3rd, 6th, and 12th month, respectively,
compared with 32 %, 38 %, 46 %, and 62 % of RA patients
with normal serum MMP-3 at the same time points.
Further analysis showed 38 %, 50 %, and 56 % of
progressive patients with normal CRP at the first, third,
and sixth months, respectively, compared with 87 % of
progressive patients with continuously elevated serum
MMP-3 for more than six months (data not shown).
Serum MMP-3 was significantly higher in the progressive
group than in the non-progressive group at baseline and
the 1st, 3rd, 6th, and 12th months (all P < 0.05). Survival
curves were used to show the ratio of patients with
elevated disease activity indicators during follow-up and
log-rank tests revealed significant differences in the sur-
vival curves of patients with elevated serum MMP-3 and
CRP between progressive and non-progressive groups
(both P < 0.05, Fig. 2). The ANOVA for repeated measures
analysis and multiple comparisons tests further confirmed
the difference in dynamic serum MMP-3 between these
two groups (data not shown).
Predictors of one-year radiographic progression
Among the baseline characteristics, serum MMP-3, total
Sharp score, joint narrow score and erosion score were
significantly higher in the progressive group than in the
non-progressive group (all P < 0.05, Table 1), while there
was no significant difference in age, sex, core disease
activity indicators, functional limitation, RF or anti-CCP
positive rate, or the percentage of DMARD- or
corticosteroid-naïve patients at baseline between progres-
sive and non-progressive groups (all P > 0.05). ROC curve
analysis showed that the predictive accuracy of serum
MMP-3 for one-year radiographic progression was 0.721
with a cutoff point of 159 ng/ml (P = 0.010, PPV 46.7 %
and NPV 92.3 %), and the predictive accuracy of total
Sharp score was 0.753 with a cutoff point of 15 (P = 0.003,
PPV 54.5 % and NPV 88.2 %). Univariate logistic regression
showed that elevated serum MMP-3 (>159 ng/ml) and
total Sharp score (>15) at baseline were significant predic-
tors of one-year radiographic progression (all P < 0.05,
Table 3). Multivariate logistic regression analysis was per-
formed to control confounding factors which included all
the baseline parameters mentioned above and showed that
high serum MMP-3 (>159 ng/ml) and high total Sharp
score (>15) were included in the final equation while other
parameters were excluded (data not shown).
At the first month follow-up, CRP and serum MMP-3
were significantly higher in the progressive group than in
non-progressive group (all P < 0.05, Fig. 1), while other
disease activity indicators showed no significant differ-
ences between these two groups (all P > 0.05). ROC curve
analysis showed that the predictive accuracy of CRP for
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one-year radiographic progression was 0.680 with a cut-
off point of 1.76 mg/dl (P = 0.037, PPV 66.7 % and NPV
78.7 %), and serum MMP-3 was 0.758 with a cutoff
point of 264 ng/ml (P = 0.003, PPV 64.7 % and NPV
87.2 %). Univariate logistic regression showed that CRP
(>1.76 mg/dl) and serum MMP-3 (>264 ng/ml) at the
first month were significant predictors of one-year
radiographic progression (all P < 0.05, Table 3).
At the third month follow-up, serum MMP-3 was sig-
nificantly higher in the progressive group than that in
the non-progressive group (P = 0.002, Fig. 1). ROC
curve analysis showed that the predictive accuracy of
serum MMP-3 for one-year radiographic progression
was 0.766 with a cutoff point of 178 ng/ml (P < 0.001,
PPV 64.7 % and NPV 87.2 %). Univariate logistic re-
gression showed that serum MMP-3 at the third month
(>178 ng/ml) was a significant predictor of one-year
radiographic progression (all P < 0.01, Table 3).
At the six month follow-up, 28SJC, CRP, and serum
MMP-3 were significantly higher in the progressive
group than in the non-progressive group (all P < 0.05,
Fig. 1). ROC curve analysis showed that the predictive
Table 2 Dynamic disease activity indicators and serum MMP-3 during one year follow-up
Disease activity indicators 1st month 3rd month 6th month 12th month
28TJC, median (IQR) 4 (1 ~ 9)*** 2 (0 ~ 4)*** 0 (0 ~ 4)*** 1 (0 ~ 5)***
28SJC, median (IQR) 2 (0 ~ 4)*** 0 (0 ~ 3)*** 0 (0 ~ 1)*** 0 (0 ~ 1)***
Pain VAS, median (IQR) 2.0 (1.7 ~ 4.0)*** 2.0 (0 ~ 3.0)*** 1.0 (0 ~ 2.8)*** 1.0 (0 ~ 3.0)***
PtGA, median (IQR) 3.0 (3.0 ~ 5.0)*** 3.0 (1.0 ~ 4.0)*** 2.0 (0.3 ~ 3.0)*** 2.0 (0 ~ 3.8)***
PrGA, median (IQR) 3.0 (2.3 ~ 4.0)*** 2.0 (1.0 ~ 4.0)*** 2.0 (0 ~ 3.0)*** 2.0 (0 ~ 3.0)***
HAQ, median (IQR) 0.28 (0 ~ 0.94)*** 0.15 (0 ~ 0.50)*** 0 (0 ~ 0.25)*** 0 (0 ~ 0.46)***
CRP, mg/dl, median (IQR) 0.44 (0.33 ~ 1.19)*** 0.33 (0.30 ~ 0.95))*** 0.34 (0.18 ~ 0.49)*** 0.33 (0.30 ~ 0.89)***
Normal CRPa, % 54 59 77 70
ESR, mm/h, median (IQR) 34 (18 ~ 48)*** 29 (16 ~ 38)*** 21 (15 ~ 36)*** 26 (13 ~ 42)***
Norma ESRb, % 27 38 41 39
DAS28c, median (IQR) 3.5 (2.6 ~ 4.4)*** 2.7 (2.0 ~ 3.9)*** 2.2 (1.5 ~ 3.2)*** 2.6 (1.5 ~ 3.3)***
Remission, % 27 43 53 48
LDA, % 20 20 20 21
MDA, % 44 30 20 26
HDA, % 9 7 7 5
SDAId, median (IQR) 14.5 (7.6 ~ 24.2)*** 8.9 (4.1 ~ 17.5)*** 5.3 (1.0 ~ 12.0)*** 6.4 (0.3 ~ 12.3)***
Remission, % 7 18 39 34
LDA, % 34 41 36 38
MDA, % 38 30 16 19
HDA, % 21 11 9 9
CDAIe, median (IQR) 13.7 (7.1 ~ 22.8)*** 8.0 (4.0 ~ 15.9)*** 4.5 (1.0 ~ 11.5)*** 5.5 (0 ~ 11.0)***
Remission, % 7 18 39 38
LDA, % 34 45 36 36
MDA, % 34 26 16 16
HDA, % 25 11 9 11
Serum MMP-3, ng/ml, median (IQR) 112 (49 ~ 347) 130 (32 ~ 183) 74 (32 ~ 183)* 52 (32 ~ 116)***
Normal serum MMP-3f, % 32 38 46 62
RF, mg/ml, median (IQR) 119 (39 ~ 252)*** 72 (20 ~ 169)*** 49 (14 ~ 137)*** 78(16 ~ 142)***
Anti-CCP, U/ml, median (IQR) 85 (11 ~ 300)** 53 (13 ~ 296)*** 65 (16 ~ 297)** 112(14 ~ 300)*
Pain VAS pain visual analogue scale, 28TJC 28-joint tender joint count, 28SJC 28-joint swollen joint count, PtGA patient global assessment of disease activity,
PrGA provider global assessment of disease activity, HAQ health assessment questionnaire, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS28 Disease
Activity Score 28-joint assessment, SDAI simplified disease activity index, CDAI clinical disease activity index, LDA low disease activity, MDA moderate disease activity,
HDA high disease activity, MMP-3 matrix metalloproteinase-3, RF rheumatoid factor, anti-CCP anti-cyclic citrullinated peptide antibody
*P < 0.05, **P < 0.01, ***P < 0.001. Compared between each time point and baseline by Wilcoxon matched-pairs signed ranks sum test
anormal CRP: <0.5 mg/dl; bnormal ESR: <20 mm/h (female) or <15 mm/h (male); cDAS28-remission: <2.6; DAS28-LDA:2.6 ~ 3.2, DAS28-MDA:3.2 ~ 5.1, DAS28-HDA:>5.1;
dSDAI-remission: <3.3; SDAI-LDA: 3.3 ~ 11.0, SDAI-MDA: 11.0 ~ 26.0, SDAI-HDA: >26.0; eCDAI-remission: <2.8; CDAI-LDA: 2.8 ~ 10.0, CDAI-MDA: 10.0 ~ 22.0, CDAI-HDA: >22.0;
fnormal serum MMP-3: <60 ng/ml (female) or <120 ng/ml (male)
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Fig. 1 (See legend on next page.)
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accuracy of CRP for one-year radiographic progression
was 0.681 with a cutoff point of 0.64 mg/dl (P = 0.035,
PPV 58.3 % and NPV 79.5 %), and serum MMP-3 was
0.830 with a cutoff point of 161 ng/ml (P < 0.001, PPV
75.0 % and NPV 90.0 %). Univariate logistic regression
showed that CRP (>0.64 mg/dl) and serum MMP-3
(>161 ng/ml) at the sixth month were significant predic-
tors of one-year radiographic progression (all P < 0.05,
Table 3).
Dynamic serum MMP-3 and T2T strategy
There were 40 (71 %) patients who achieved the thera-
peutic target at the 12th month. In the T2T-achieving
group, seven (18 %) patients developed radiographic pro-
gression, of which six (86 %) showed elevated serum
MMP-3 at baseline, first, third, and sixth months. There
was no significant difference of disease activity (measured
by SDAI) between progressive and non-progressive
patients in the T2T-achieving group throughout one year,
while serum MMP-3 was significantly higher in progressive
patients than in non-progressive patients at baseline, 1st,
3rd, 6th or 12th month (all P < 0.05, Fig. 3). ROC curve
analysis showed that the predictive accuracy of serum
MMP-3 at baseline, first, third and sixth month for one-
year rapid radiographic progression was 0.745, 0.801,
0.784, and 0.840, respectively, with cutoff points of 242,
297, 193, and 161 ng/ml, respectively (all P < 0.05). Univari-
ate logistic regression showed that elevated serum MMP-
3s (> cutoff points) at baseline and first, third and sixth
month were significant predictors of one-year rapid radio-
graphic progression (Table 4). In the T2T non-achieved
group (n = 16, 29 %), nine (56 %) developed radiographic
progression, of which eight (89 %) showed elevated serum
MMP-3 at the sixth month.
There were five patients with LDA at baseline and
four of them achieved remission at the 6th month with-
out radiographic progression at the 12th month; mean-
while, their serum MMP-3 remained normal from
baseline to the 6th month. The other patient with LDA
(SDAI = 8.9) at baseline became worse with MDA
(SDAI = 24.3) and developed radiographic progression
at the 12th month together with continuously elevated
serum MMP-3 throughout the whole year.
Patients with RRP after one year
There were five patients with RRP at the one-year
follow-up, of which four patients did not achieve the
therapeutic target. Baseline serum MMP-3 and total
Sharp score were significantly higher in patients with
RRP than in other patients (both P < 0.05), while there
was no significant difference in age, disease duration,
other core disease activity indicators, functional limita-
tion, RF or anti-CCP positive rate between patients
with or without RRP (all P > 0.05). Baseline SDAI of
these patients with RRP was 20.5 (16.0 ~ 30.8). One pa-
tient with RRP achieved LDA at the first month and
remained there for the entire year, while the others
failed to achieve the therapeutic target during one-year
follow-up. Serum MMP-3 at the third month and
28SJC, PtGA, PrGA, and SDAI at the sixth month were
significantly higher in patients with RRP than in other
patients (all P < 0.05). ROC curve analysis showed that
the predictive accuracy of serum MMP-3 at the third
month for one-year RRP was 0.784 with a cutoff point
of 178 ng/ml (P = 0.037, PPV 23.5 % and NPV 97.4 %).
Univariate logistic regression showed that serum MMP-
3 (>178 ng/ml) at the third month was a significant pre-
dictor of one-year RRP (odds ratio (OR) = 11.692, 95 %
confidence interval (CI): 1.196 ~ 114.312, P = 0.035).
Discussion
This research performed a prospective cohort study com-
paring serum MMP-3 with core disease activity indicators
for predicting radiographic progression in RA. Dynamic
serum MMP-3 and core disease activity indicators were
analyzed by repeated measures analysis and log-rank tests.
The results showed continuously elevated serum MMP-3
for 3 ~ 6 months in radiographic progressive patients who
have achieved the therapeutic target even when combined
with normal CRP. Further analyses of ROC curve and uni-
variate logistic regression analysis showed that elevated
serum MMP-3 at baseline and the first, third, and sixth
month, compared with CRP only at the first month, were
significant predictors for one-year radiographic progression
in RA. Subgroup studies showed that dynamic serum
MMP-3 might be especially helpful for predicting radio-
graphic progression in the T2T-achieving group, and
(See figure on previous page.)
Fig. 1 Dynamic disease activity indicators and serum MMP-3 between non-progressive and progressive patients. *P < 0.05, **P < 0.01, ***P < 0.001.
Compared between non-progressive and progressive groups by Mann–Whitney rank-sum test. White triangle: dotted line of 60 represents the upper limit
of normal serum MMP-3 in females (upper limit of normal serum MMP-3 in males is not shown); Pain VAS pain visual analogue scale, 28TJC 28-joint tender
joint count, 28SJC 28-joint swollen joint count, PtGA patient global assessment of disease activity, PrGA provider global assessment of disease activity, HAQ
health assessment questionnaire, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS28 Disease Activity Score 28-joint assessment,
SDAI simplified disease activity index, CDAI clinical disease activity index, MMP-3 matrix metalloproteinase-3, RF rheumatoid factor, anti-CCP
anti-cyclic citrullinated peptide antibody. Data are represented by median and interquartile range
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Fig. 2 (See legend on next page.)
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elevated serum MMP-3 at the third month was a signifi-
cant predictor of one-year RRP in patients with RRP.
Joint destruction in RA may reduce the quality of life
and cause severe disability. Conventional X-ray radiog-
raphy is the most commonly used method to reflect
existing joint damage. Several scoring systems, such as
the Larsen and Sharp score systems, have been devel-
oped for quantitative evaluation. The Sharp score system
was established for the assessment of hands in 1971 and
modified by van der Heijde in 1985 who optimized the
scoring procedures and added the assessment of feet
[16]. The Sharp/van der Heijde score system which is
sensitive for detecting radiographic change has been
widely used in clinical research of RA [19].
The Sharp/van der Heijde score can be summed in sev-
eral ways: total erosion of hands and/or feet; total joint
space narrowing of hands and/or feet; and summation of
erosions and joint space narrowing, called “total score” of
hands and/or feet [16]. Metacarpophalangeal (MCP) joints,
proximal interphalangeal (PIP) joints and wrists are the
most commonly involved joints in RA (78 % ~ 91 %), while
foot involvement appeared in less than half of RA patients
(43 %) [20]. We applied the Sharp/van der Heijde score
containing MCP, PIP and wrists in this study.
Previous studies have confirmed a significant correl-
ation between disease activity and joint damage. Both
ACR and EULAR recommendations on treatment of RA
emphasize tight control of disease activity and thera-
peutic target of remission or LDA [2, 21]. Our study was
designed as a real world prospective cohort study using
the T2T strategy. The therapeutic target was achieved at
the 12th month by 71 % of the patients which is com-
parable with published rates of clinical studies (31 % ~
75 %) [22–26]. CRP significantly decreased after one
month and returned to normal after three and six
months in 59 % and 77 % of the patients, respectively.
However, 29 % of the patients showed radiographic pro-
gression after one year, and most core disease activity in-
dicators except for ESR at the 12th month were
significantly higher in the progressive group than in the
non-progressive groups although there was no signifi-
cant difference at baseline. To exclude the joint damage
progression due to not being able to be intensively
treated, we performed a subgroup analysis of T2T-
achieving patients and found that seven (18 %) of them
had radiographic progression. These results indicate the
limitation of the T2T strategy focused on disease activity
in the prevention of joint destruction and the limitation
Table 3 Performance of disease activity indicators as predictors for one-year radiographic progressiona
Disease
activity indicators
Accuracy P 95 % CI Cutoff point PPV (%) NPV (%) OR (95 % CI) P
Baseline
Serum MMP-3 0.721 0.010 0.572 ~ 0.870 159 ng/ml 46.7 92.3 10.500 (2.097 ~ 52.581) 0.004
Total Sharp score 0.753 0.003 0.613 ~ 0.893 15 54.5 88.2 9.000 (2.359 ~ 34.334) 0.001
1st month
CRP 0.680 0.037 0.525 ~ 0.835 1.76 mg/dl 66.7 78.7 7.400 (1.567 ~ 34.935) 0.011
Serum MMP-3 0.758 0.003 0.605 ~ 0.911 264 ng/ml 64.7 87.2 12.467 (3.175 ~ 48.950) < 0.001
3rd month
Serum MMP-3 0.766 0.002 0.606 ~ 0.926 178 ng/ml 64.7 87.2 15.857 (3.412 ~ 73.687) < 0.001
6th month
28SJC 0.667 0.052 0.503 ~ 0.832 NA NA NA NA NA
CRP 0.681 0.035 0.525 ~ 0.838 0.64 mg/dl 58.3 79.5 5.444 (1.395 ~ 21.244) 0.015
Serum MMP-3 0.830 < 0.001 0.696 ~ 0.963 161 ng/ml 75.0 90.0 27.000 (5.834 ~ 24.962) < 0.001
aAccuracy of predictive value was determined by ROC curve analysis; OR of predictors was determined by univariate logistic regression analysis according to the cutoff point
28SJC 28-joint swollen joint count, PrGA provider global assessment of disease activity, CRP C-reactive protein, ESR erythrocyte sedimentation rate, MMP-3 matrix
metalloproteinase-3, RF rheumatoid factor, anti-CCP anti-cyclic citrullinated peptide antibody, DAS28 Disease Activity Score 28-joint assessment, SDAI simplified
disease activity index, PPV positive predictive value, NPV negative predictive value, ROC receiver operating characteristic; OR odds ratio, CI confidence interval, NA
not applicable
(See figure on previous page.)
Fig. 2 Survival curves for the ratio of patients with abnormal disease activity indicators and serum MMP-3 between non-progressive and progressive
patients. P values were determined by log-rank tests between non-progressive and progressive groups. Pain VAS pain visual analogue scale,
28TJC 28-joint tender joint count, 28SJC 28-joint swollen joint count, PtGA patient global assessment of disease activity, PrGA provider global
assessment of disease activity, HAQ health assessment questionnaire, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS28 Disease Activity
Score 28-joint assessment, SDAI simplified disease activity index, CDAI clinical disease activity index, MMP-3 matrix metalloproteinase-3, RF rheumatoid
factor, anti-CCP anti-cyclic citrullinated peptide antibody
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of dynamic CRP in predicting radiographic progression.
A new biomarker for predicting radiographic progres-
sion in RA is needed.
As a proteinase from local joints, MMP-3 can be de-
tected in peripheral blood. MMP-3 was first measured
by a substrate cleavage assay or zymography at 1986.
However, the substrate cleavage assay lacked conveni-
ence, specificity or sensitivity, while zymography was
labor-intensive and semi-quantitative. The assay meth-
odology was modified to ELISA using horseradish perox-
idase (HRP) as the detection enzyme and colorimetric
signal in 1992. The specificity of MMP-3 detection is
very important as other MMPs, such as MMP-1, MMP-
2 and MMP-9, have a similar structure and same origin
which are produced at the same site or by the same cells
[27]. Here, we used the AESKULISA DF MMP-3 kit to
detect serum MMP-3 by sandwich ELISA using micro-
plates coated with monoclonal anti-human MMP-3 anti-
body and no cross-reactivity to other antigens including
MMP-1, MMP-2 or MMP-9 had been found according
to the performance data of this kit [8].
Previous studies have found that baseline serum
MMP-3 is positively correlated with disease activity and
joint destruction at entry and it can predict radiographic
progression longitudinally in early RA [28]. In this study,
we also found that high serum MMP-3 and high total
Sharp score at baseline could predict one year radiographic
progression. Compared to radiographic assessment, espe-
cially X-ray which cannot be performed very frequently,
serum MMP-3 might be more suitable for dynamic moni-
toring with an interval as short as 1 ~ 3 months. Our dy-
namic data showed that serum MMP-3 is significantly
higher in progressive patients than in non-progressive pa-
tients for an entire year and 87 % of progressive patients
showed continuously elevated serum MMP-3 for more
than six months, compared with 44 % of progressive pa-
tients with elevated CRP after six months. ROC curve and
univariate logistic regression analyses showed that
serum MMP-3 at baseline and the first, third, and
sixth month were significant predictors of one-year
radiographic progression. A recent systematic litera-
ture review of 57 clinical studies also found that
time-integrated measure of disease activity indicators
positively correlated with radiographic progression
which implies that monitoring of dynamic disease ac-
tivity indicators might be more valuable in predicting
radiographic progression [29]. All these findings indi-
cate that dynamic monitoring of serum MMP-3 may be
helpful for predicting radiographic progression in RA and
continuously elevated serum MMP-3 for 3 ~ 6 months
may be a significant predictor of one-year radiographic
progression.
Young-Min et al. reported elevated baseline serum
MMP-3 as a predictor of two-year radiographic progression
Table 4 Performance of dynamic serum MMP-3 as predictor for one-year radiographic progressiona
Serum MMP-3 Accuracy P 95 % CI Cutoff point PPV (%) NPV (%) OR (95 % CI) P
Baseline 0.745 0.044 0.564 ~ 0.925 242 ng/ml 37.5 95.8 13.800 (1.464 ~ 130.070) 0.022
1st month 0.801 0.013 0.606 ~ 0.996 297 ng/ml 55.6 93.5 18.125 (2.592 ~ 126.721) 0.003
3rd month 0.784 0.020 0.564 ~ 1.003 193 ng/ml 55.6 93.5 18.125 (2.592 ~ 126.721) 0.003
6th month 0.840 0.005 0.658 ~ 1.022 161 ng/ml 62.5 93.8 25.000 (3.302 ~ 189.259) 0.002
aAccuracy of predictive value was determined by ROC curve analysis; ORs of predictors were determined by univariate logistic regression analysis according to the
cutoff point
MMP-3 matrix metalloproteinase-3, PPV positive predictive value, NPV negative predictive value, ROC receiver operating characteristic, OR odds ratio, CI confidence interval
Fig. 3 Dynamic disease activity and serum MMP-3 between non-progressive and progressive patients in T2T-achieving group (a. Dynamic disease
activity defined by SDAI; b. Dynamic serum MMP-3). *P < 0.05, **P < 0.01. Compared between non-progressive and progressive groups by Mann–Whitney
rank-sum test. White triangle: dotted line of 60 represents the upper limit of normal serum MMP-3 in females (upper limit of normal serum MMP-3 in males
is not shown). SDAI simplified disease activity index, MMP-3 matrix metalloproteinase-3. Data are represented by median and interquartile ranges
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with a cutoff point of 85.79 ng/ml and also a strong inde-
pendent predictor of radiographic progression at 8.2 years
with a cutoff point of 71.6 ng/ml, in which the cutoff points
of serum MMP-3 were within the normal range of male
(17.3 ~ 59.7 ng/ml in female and 36.9 ~ 121 ng/ml in male,
Daiichi Fine Chemical, Toyama, Japan) [30, 31]. Here we
found that elevated serum MMP-3 at baseline and the first,
third and sixth months were significant predictors of one-
year radiographic progression with cutoff points of 159
ng/ml, 264 ng/ml, 178 ng/ml, and 161 ng/ml, respectively.
Considering the close relationship of sensitivity, specificity
and PPV, NPV, we performed ROC curve analysis with
Youden index to determine the cutoff points and found
that the cutoff points in both female and male pa-
tients (such as 161 ng/ml at the 6th month) were higher
than the upper limit of the normal range which will be
more applicable for clinical use.
The reduction of serum MMP-3 was recently considered
as a secondary therapeutic target, particularly in biological
therapy with TNF-α inhibitor, IL-6 receptor blocker or
T-cell costimulation inhibitor therapies [32–34]. Urata
et al. reported a study of 243 early RA patients who were
divided into routine care, DAS28 driven therapy, MMP-3
driven therapy or both DAS28 and MMP-3 driven therapy
groups and the result of one-year follow-up showed that
the MMP-3 driven therapy group had the greatest propor-
tion to achieve radiographic non-progression among these
four groups, which implied that serum MMP-3 might be a
supplemental predictor of radiographic progression in
clinical practice [25]. According to ACR/EULAR recom-
mendations on treatment of RA, the therapeutic target
should be achieved in 3 ~ 6 months [2, 14, 21]. In our
data, there were nine (16 %) patients with continuous
elevated serum MMP3 at 3 ~ 6 months who had achieved
the therapeutic target at that time, but finally developed
radiographic progression. If these patients were treated
more aggressively until serum MMP-3 returned to nor-
mal, the possibility of radiographic progression after one
year might be decreased. The combined strategy of both
SDAI or CDAI and serum MMP-3 driven therapy is worth
further study.
There are several limitations of this study. Firstly, it
was designed as a real world prospective cohort study.
All patients were recruited at a single center and treated
with various medications. Further multicenter studies of
the combined strategy of both disease activity and serum
MMP-3 driven therapy with the same treatment in all
centers are needed. Secondly, all patients recruited in
this study had poor prognostic features and 93 % of
them had bony erosion at baseline which might con-
found prediction of radiographic progression. More new
onset RA patients without bony erosion are needed in
future to investigate whether serum MMP-3 could pre-
dict radiographic progression in these patients.
Conclusions
Our data show that continuously elevated serum MMP-3
for 3 ~ 6 months predicted one-year radiographic progres-
sion which implies that monitoring of dynamic serum
MMP-3 combined with core disease activity indicators
may be more helpful for predicting radiographic progres-
sion and treatment decisions in RA.
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